Cranioencephalic News
-
Silk Road Medical Announces FDA Approval of Expanded Indications for the ENROUTE Transcarotid Stent System
Silk Road Medical, Inc.?(Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that that the U.S. Food and Drug Administration (FDA) approved expanded indications for the ENROUTE stent to include patients at standard risk for adverse events from carotid endarterectomy (CEA). Previously, the stent was approved for use only in patients with ...
-
SeaSpine Announces CE Mark Certification of 7D Surgical Cranial Module and Percutaneous Spine Module for Minimally Invasive Spine Surgery
CARLSBAD, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it received simultaneous CE Mark certification for its Cranial Module and Percutaneous Spine Module for the 7D FLASH™ Navigation System. This achievement expands the ...
By 7D Surgical
-
Galaxy Medical Enrolls First Patients in SPACE-AF Study SAN
SAN CARLOS, California, September 20, 2021 — Galaxy Medical announced today the initiation of the SPACE-AF study with enrollment of the first two patients at Southlake Regional Health Centre in Newmarket, Canada. In the study, the CENTAURI Pulsed Electric Field (PEF) ablation system will be used to ablate both the pulmonary veins and posterior walls in patients with persistent atrial ...
-
SeaSpine Announces FDA 510(k) Clearance of 7D Surgical Percutaneous Spine Module for Minimally Invasive Surgery
CARLSBAD, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the FDA 510(k) clearance of its 7D Percutaneous Spine Module for minimally invasive surgery. This represents a new application and increased functionality for its 7D Flash™ ...
By 7D Surgical
-
First Patient Treated in Polyganics’ ENCASE II Trial for Innovative Dura Sealant Patch, LIQOSEAL
Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, today announced treatment of the first patient in its ENCASE II clinical trial for LIQOSEAL. LIQOSEAL is an easy-to-use, synthetic dura sealant patch indicated for use as an adjunct to standard methods of cranial dural repair, to provide watertight closure of the dura mater and ...
-
NeuroSigma Continues to Build a Substantial Global Bioelectronics Patent Portfolio
NeuroSigma, Inc., a Los Angeles-based bioelectronics company that is commercializing trigeminal nerve stimulation (TNS) technology to treat neurological and neuropsychiatric disorders, announced today that the following patents have issued or received notices of allowance in Canada and Japan: Canadian patent no. 2776694 entitled Devices, Systems, and Methods for Treatment of Neuropsychiatric ...
-
NeuroSigma Successfully Obtains HCPCS Codes from CMS for the Monarch eTNS System
NeuroSigma, Inc., a Los Angeles-based bioelectronics company that is commercializing Trigeminal Nerve Stimulation (TNS) technology for treating neurological and neuropsychiatric disorders, announces that the Centers for Medicare & Medicaid Services ("CMS") is establishing two new Level II Healthcare Common Procedure Coding System ("HCPCS") codes for the Monarch eTNS System®, effective ...
-
Synaptive Medical Announces Close of $17M Preferred Share Financing
Synaptive Medical, a leader in automation and robotics, announced today it has completed a sale of preferred equity totaling $17,000,000 USD. The investment was made by Sensegain Group, a leading asset management firm in China. Ms. Jing Yang, Board Member & Senior Partner of Sensegain, will join Synaptive’s Board of Directors. Sensegain Group is headquartered in Beijing with multiple ...
-
Renishaw collaboration receives health and wellbeing award shortlist
Additive-manufacture for Design-led Efficient Patient Treatment (ADEPT) has been shortlisted for a Collaborate to Innovate award, in the Health and Wellbeing category. The collaborative project aims to revolutionise maxillofacial implants through design and laser melting by drawing on expertise from several partners, including global engineering company Renishaw. The awards, organised by The ...
By Renishaw plc
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you